20 plus years of expertise in developing APIs. Recognised for rich chemistry experience, quality, manufacturing capabilities, regulatory and IP capabilities

    Read more

  • Formulations

    One of the world leaders in developing & manufacturing branded/non-branded generics. More than 200 marketed products and 150 ANDAs filed across most therapeutic areas.

    Read more

  • ARV

    One of the world’s largest global producer of anti-retroviral drugs. Over 30 US FDA and WHO PQ approved ARV molecules and combinations in ARV portfolio.

    Read more

  • Biosimilars

    Our Biosimilar program focuses on development, manufacturing and commercialization of high value complex biosimilars including monoclonal antibodies.

    Read more

News & Events

  • 16 Dec 2015
  • Correct trademark name of Ledipasvir-Sofosbuvir is 'Ledifos'
  • This is with reference to the press release dated 9th December 2015 on the DCGI approval for Ledipasvir-Sofosbuvir. Hetero would like to clarify that there was an error in the brand name of the fixed-dose combination drug 'Ledipasvir-Sofosbuvir'. It was published as Ledisof. Read more